Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Other Operating Expenses (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Other Operating Expenses for 13 consecutive years, with -$1000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Operating Expenses changed N/A to -$1000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $46.1 million, a 61.53% decrease, with the full-year FY2024 number at $61.5 million, down 59.63% from a year prior.
  • Other Operating Expenses was -$1000.0 for Q3 2025 at Gyre Therapeutics, down from $17.2 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $106.4 million in Q4 2023 to a low of -$5.3 million in Q3 2023.
  • A 5-year average of $15.0 million and a median of $1.9 million in 2021 define the central range for Other Operating Expenses.
  • Peak YoY movement for Other Operating Expenses: tumbled 117.56% in 2022, then surged 180469.49% in 2023.
  • Gyre Therapeutics' Other Operating Expenses stood at $68.7 million in 2021, then plummeted by 100.09% to -$59000.0 in 2022, then soared by 180469.49% to $106.4 million in 2023, then plummeted by 83.06% to $18.0 million in 2024, then plummeted by 100.01% to -$1000.0 in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Other Operating Expenses are -$1000.0 (Q3 2025), $17.2 million (Q2 2025), and $10.8 million (Q1 2025).